Stay updated with breaking news from Small Molecule Switching. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU...
/PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several...
Share this article Share this article EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix's recent report, RealTime Dynamix™: Inflammatory Bowel Disease (EU). The report sampled 246 EU5 gastroenterologists in November and December of 2020. While both new, subcutaneous market entrants have mostly gained prescribing momentum by cannibalizing their corresponding IV formulations, AbbVie's Humira stand...